Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Intrinsa Needs More Safety Studies In Face Of Potential Off-Label Use

Executive Summary

Further safety studies of Procter & Gamble's testosterone patch Intrinsa are necessary prior to approval because of the potential for broad off-label use of the female sexual dysfunction therapy, FDA's Reproductive Health Drugs Advisory Committee said Dec. 2
Advertisement

Related Content

A New Dawn For Female Sex Dysfunction Drugs? FDA Meeting Cheers Sponsors
BioSante LibiGel Study Design Changes Could Yield Better Results For Sexual Dysfunction
BioSante LibiGel Study Design Changes Could Yield Better Results For Sexual Dysfunction
BioSante Sees No Adverse Effect On LibiGel From Flibanserin Review
BioSante Sees No Adverse Effect On LibiGel From Flibanserin Review
Full Safety Data For Female Sexual Disorder Drugs Could Come Post-Approval
P&G withdraws Intrinsa NDA
Female Sexual Dysfunction Guidance Should Be Revised, Intrinsa Cmte. Says
Prempro Cancer Risk Addressed In 550,000 Physician Letters, Label Review
Prempro Cancer Risk Addressed In 550,000 Physician Letters, Label Review

Topics

Advertisement
UsernamePublicRestriction

Register

PS045060

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel